Hematopoietic Stem Cell TransplantationHematopoietic Stem CellsTransplantation, HomologousCyclophosphamideStem Cell TransplantationTransplantation, AutologousTransplantation ConditioningGraft vs Host DiseasePeripheral Blood Stem Cell TransplantationHematologic NeoplasmsStem CellsBone Marrow TransplantationTransplantation ChimeraTreatment OutcomeTissue DonorsBusulfanCord Blood Stem Cell TransplantationWhole-Body IrradiationHematopoiesisGraft SurvivalMyeloablative AgonistsHematopoietic Stem Cell MobilizationHistocompatibility TestingHistocompatibilityAntigens, CD34Retrospective StudiesRecurrenceLeukemiaImmunosuppressive AgentsGraft vs Leukemia EffectChimerismLiver TransplantationCombined Modality TherapyRemission InductionVidarabineAntineoplastic Combined Chemotherapy ProtocolsBone Marrow CellsHematologic DiseasesCell DifferentiationMultiple MyelomaHepatic Veno-Occlusive DiseaseMesenchymal Stem Cell TransplantationDisease-Free SurvivalSurvival RateTime FactorsHLA AntigensSurvival AnalysisLeukemia, Myeloid, AcuteSiblingsMelphalanMyelodysplastic SyndromesUnrelated DonorsCell LineageCell TransplantationStem Cell NicheGraft vs Tumor EffectGranulocyte Colony-Stimulating FactorEmbryonic Stem CellsFlow CytometryBone MarrowTransplantation ImmunologyMice, Inbred C57BLAdult Stem CellsKidney TransplantationLymphocyte TransfusionSevere Combined ImmunodeficiencyAntineoplastic Agents, AlkylatingTransplantation, IsogeneicSalvage TherapyColony-Forming Units AssayPrecursor Cell Lymphoblastic Leukemia-LymphomaAnemia, AplasticFetal BloodAntilymphocyte SerumFollow-Up StudiesLymphoma, Non-HodgkinVincristineLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCytomegalovirus InfectionsImmunosuppressionT-LymphocytesLymphocyte DepletionDonor SelectionAcute DiseaseGraft RejectionAllograftsCells, CulturedCell SeparationEtoposidePrognosisMesenchymal Stromal CellsThiotepaImmunocompromised HostOpportunistic InfectionsCell ProliferationPluripotent Stem CellsMultipotent Stem CellsLymphoproliferative DisordersCytarabineStem Cell Factor